Novo CEO: Obesity goal within touching distance well before 2025 deadline

Novo Nordisk may be able to realize its ambition to double the size of its obesity business compared to 2019 levels three years early. A new target may be revealed soon.

Photo: Stine Bidstrup/ERH

Danish pharmaceutical giant Novo Nordisk is well on the way to achieving its 2025 goal for sales of weight loss drugs three years early. There is therefore a good chance that a new target will be revealed at the company’s upcoming capital markets day, on March 3.

”The goal will be within touching distance well before the 2025 deadline,” says CEO Lars Fruergaard Jørgensen to MarketWire, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs